TNG:EPA
Transgene SA
0,70 €
arrow_downward
-0,42%(-0,0030) 1D
8 հոկ, 10:14:20 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TNG...
Open
0,71 €
High
0,71 €
Low
0,70 €
Mkt. cap
195,48 մլն
Avg. vol.
137,31 հզր
Volume
19,68 հզր
52-wk high
1,50 €
52-wk low
0,69 €
EPS
-0,17 €
Shares outstanding
278,56 մլն
No. of employees
160
Open
0,71 €
High
0,71 €
Low
0,70 €
Mkt. cap
195,48 մլն
Avg. vol.
137,31 հզր
Volume
19,68 հզր
52-wk high
1,50 €
52-wk low
0,69 €
EPS
-0,17 €
Shares outstanding
278,56 մլն
No. of employees
160
News stories
From web sources and news partners
Bloomberg Government News
·
35 րոպե առաջ
Nasdaq-Listed Lobbying Firm Launches Capitol Hill Oversight Unit
www.marketscreener.com
·
36 րոպե առաջ
Kyivstar to Report 3Q26 Results on November 6, 2026
Stocktwits
·
46 րոպե առաջ
Why Are Nasdaq, Dow Futures Falling Premarket? MU, TSM, APLD, IONQ, HOOD, BULL, SLS In Focus
Yahoo Finance
·
1 ժամ առաջ
Prediction: The S&P 500 Will Hit 10,000 in 2027
Profile
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
About Transgene SA